New to Generics Bulletin?
Request a free trial today!
Register for our free email digests:
Register for our free email digests:
Shanghai Henlius Biotech Co. Ltd.
https://www.henlius.com/en/index.html
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Shanghai Henlius Biotech Co. Ltd.
Henlius Finds Global Partner For Ophthalmic Bevacizumab
Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essex Bio-Technology for biosimilar bevacizumab to treat ophthalmic diseases.
Cancer, Rare Disease Drugs Among New China Approvals
Rare disease and cancer treatments are front and center in the latest batch of China new drug approvals, while biosimilars are expected to move into the spotlight.
Henlius’ Trastuzumab Approved In China
Shanghai Henlius Biotech has received the first Chinese approval for a trastuzumab biosimilar version of Herceptin.
Accord Adds To Crowded EU Trastuzumab Market
Shanghai Henlius Biotech is to make history with the first China-developed monoclonal antibody biosimilar in Europe, the firm’s Zercepac (trastuzumab) biosimilar that has been licensed to Accord Healthcare.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Fosun Pharma
- Henlius Biopharmaceuticals
- Shanghai Henlius Biotech, Inc.
- Taiwan Henlix Biotech Co., Ltd.
- Hengenix Biotech